Janux Therapeutics (JANX) Revenue (2021 - 2026)

Janux Therapeutics (JANX) posted quarterly Revenue of $3.7 million for Q1 2026, down 62.67% quarter-over-quarter from $10.0 million in Q3 2025.

Janux Therapeutics (JANX) Revenue (2021 - 2026) Analysis & Trends

Janux Therapeutics (JANX) has reported Revenue for 6 consecutive years, with $3.7 million the latest figure, recorded in Q1 2026.

In Q1 2026, Revenue changed N/A year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $13.7 million (up 47.1% YoY), while the FY2025 annual figure was $10.0 million, down 5.55% from the prior year.
Revenue retreated to $3.7 million in Q1 2026 per JANX's latest filing, from $10.0 million in the prior quarter.
Across five years, Revenue topped out at $10.0 million in Q3 2025 and bottomed at $439000.0 in Q3 2024.
Historically, Revenue has averaged $3.2 million across 5 years, with a median of $2.4 million in 2022.
Annual changes were most pronounced in 2024 — Revenue slumped 82.56% — and 2025, when it jumped 2177.9%.
Janux Therapeutics' Revenue stood at $2.8 million in 2022, then slipped by 13.5% to $2.5 million in 2023, then plunged by 82.16% to $439000.0 in 2024, then surged by 2177.9% to $10.0 million in 2025, then slumped by 62.67% to $3.7 million in 2026.
Business Quant data shows JANX's Revenue at $3.7 million in Q1 2026, $10.0 million in Q3 2025, and $439000.0 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.56 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.71 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	3,001.92
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	674.14 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	1.29 Bn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	425.49 Mn
10	Janux Therapeutics	984.58 Mn	984.58 Mn	-	10.27 Mn

Download Data